- Home
- ROIV vs TECH Comparison
ROIV vs TECH Comparison
Compare ROIV & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- TECH
- Stock Information
- Founded
- ROIV 2014
- TECH 1976
- Country
- ROIV United Kingdom
- TECH United States
- Employees
- ROIV N/A
- TECH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROIV Health Care
- TECH Health Care
- Exchange
- ROIV Nasdaq
- TECH Nasdaq
- Market Cap
- ROIV 8.4B
- TECH 7.8B
- IPO Year
- ROIV N/A
- TECH 1989
- Fundamental
- Price
- ROIV $10.79
- TECH $49.15
- Analyst Decision
- ROIV Buy
- TECH Buy
- Analyst Count
- ROIV 4
- TECH 10
- Target Price
- ROIV $17.50
- TECH $73.44
- AVG Volume (30 Days)
- ROIV 5.9M
- TECH 2.3M
- Earning Date
- ROIV 05-29-2025
- TECH 05-07-2025
- Dividend Yield
- ROIV N/A
- TECH 0.65%
- EPS Growth
- ROIV N/A
- TECH N/A
- EPS
- ROIV N/A
- TECH 0.83
- Revenue
- ROIV $122,585,000.00
- TECH $1,208,770,000.00
- Revenue This Year
- ROIV N/A
- TECH $8.19
- Revenue Next Year
- ROIV N/A
- TECH $8.61
- P/E Ratio
- ROIV N/A
- TECH $59.07
- Revenue Growth
- ROIV 140.04
- TECH 4.72
- 52 Week Low
- ROIV $8.73
- TECH $46.44
- 52 Week High
- ROIV $13.06
- TECH $85.57
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- TECH 44.74
- Support Level
- ROIV $10.58
- TECH $46.35
- Resistance Level
- ROIV $11.77
- TECH $54.40
- Average True Range (ATR)
- ROIV 0.34
- TECH 2.17
- MACD
- ROIV -0.07
- TECH 0.27
- Stochastic Oscillator
- ROIV 17.65
- TECH 34.78
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.